Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells $374,185.23 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 4,159 shares of the stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $89.97, for a total transaction of $374,185.23. Following the sale, the director owned 4,159 shares of the company’s stock, valued at $374,185.23. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth also recently made the following trade(s):

• On Wednesday, April 15th, Bruce Booth sold 3,135 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.10, for a total transaction of $282,463.50.
• On Wednesday, April 15th, Bruce Booth sold 2,200 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.95, for a total transaction of $197,890.00.
• On Monday, March 2nd, Bruce Booth sold 81,866 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.13, for a total transaction of $7,378,582.58.

Kymera Therapeutics Stock Up 1.8%

NASDAQ KYMR opened at $87.71 on Friday. The stock has a market capitalization of $7.16 billion, a P/E ratio of -23.83 and a beta of 2.28. Kymera Therapeutics, Inc. has a 52-week low of $25.50 and a 52-week high of $103.00. The firm has a 50-day moving average price of $84.06 and a 200 day moving average price of $74.56.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). The firm had revenue of $2.87 million for the quarter, compared to analysts’ expectations of $14.80 million. Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The company’s revenue for the quarter was down 60.8% on a year-over-year basis. During the same period in the prior year, the company earned ($0.88) earnings per share. On average, equities research analysts expect that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in KYMR. Baker BROS. Advisors LP increased its holdings in Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock valued at $673,620,000 after buying an additional 2,005,813 shares in the last quarter. Avoro Capital Advisors LLC increased its holdings in Kymera Therapeutics by 17.7% in the fourth quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after buying an additional 1,124,747 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Kymera Therapeutics by 20.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after buying an additional 1,061,957 shares in the last quarter. Vanguard Group Inc. increased its holdings in Kymera Therapeutics by 15.6% in the fourth quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after buying an additional 845,922 shares in the last quarter. Finally, Holocene Advisors LP purchased a new position in Kymera Therapeutics in the third quarter valued at about $47,563,000.

Kymera Therapeutics News Summary

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Several sell‑side analysts maintain bullish views and have raised price targets this quarter (Piper Sandler, Morgan Stanley, Stephens, BTIG), supporting demand for the shares and helping lift sentiment.
• Positive Sentiment: Small institutional increases were reported (several asset managers added modest stakes), which can provide incremental buying support in a thin float biotech. Institutional Activity
• Neutral Sentiment: Director Bruce Booth sold multiple tranches (April 14–15) totaling several thousand shares, but those sales were executed under a pre‑arranged Rule 10b5‑1 plan, which investors often view as scheduled liquidity rather than a change in insider conviction. SEC Form 4
• Negative Sentiment: COO Jeremy G. Chadwick sold a series of shares (total reported ~6,551 shares across April 14–15 at ~ $90 each) that reduced his stake; these transactions were disclosed without a 10b5‑1 designation, which can raise investor concern and likely pressured intraday trading. SEC Filing
• Negative Sentiment: Another insider, Noah Goodman, sold ~1,347 shares on April 14 (~$90/share) without a stated 10b5‑1 plan, further trimming insider ownership and adding to near‑term selling pressure. SEC Filing
• Negative Sentiment: Fundamentals remain a caution: the company missed Q4 EPS and revenue estimates in February (significant revenue shortfall year‑over‑year), which keeps the longer‑term risk profile elevated for a clinical‑stage biotech. Earnings & Key Metrics

Analysts Set New Price Targets

Several research firms recently issued reports on KYMR. Barclays increased their price target on shares of Kymera Therapeutics to $133.00 and gave the stock an “overweight” rating in a report on Tuesday, January 27th. BTIG Research cut their price target on shares of Kymera Therapeutics from $138.00 to $134.00 and set a “buy” rating for the company in a report on Thursday, February 26th. Piper Sandler increased their price target on shares of Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a report on Thursday, February 26th. Stephens increased their price target on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the stock an “overweight” rating in a report on Monday, March 2nd. Finally, Wall Street Zen cut shares of Kymera Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. One investment analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Kymera Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $118.90.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.